Crispr Therapeutics (NASDAQ:CRSP) had its price objective hoisted by Oppenheimer from $65.00 to $80.00 in a research report released on Monday, November 25th, The Fly reports. Oppenheimer currently has an outperform rating on the stock. Oppenheimer also issued estimates for Crispr Therapeutics’ FY2019 earnings at $0.59 EPS, Q1 2020 earnings at ($0.89) EPS, Q2 2020 earnings at ($0.97) EPS, Q3 2020 earnings at ($1.32) EPS, Q4 2020 earnings at ($1.42) EPS, FY2020 earnings at ($4.63) EPS, FY2021 earnings at ($4.47) EPS, FY2022 earnings at ($4.98) EPS and FY2023 earnings at ($2.03) EPS.
Other equities analysts also recently issued reports about the stock. BTIG Research raised their price target on shares of Crispr Therapeutics from $51.00 to $59.00 and gave the stock a positive rating in a research note on Tuesday, July 30th. ValuEngine upgraded shares of Crispr Therapeutics from a sell rating to a hold rating in a research report on Friday, November 1st. Canaccord Genuity lifted their price target on shares of Crispr Therapeutics from $72.00 to $80.00 and gave the company a positive rating in a research report on Wednesday, November 20th. BidaskClub upgraded shares of Crispr Therapeutics from a hold rating to a buy rating in a research report on Friday, November 15th. Finally, TheStreet upgraded shares of Crispr Therapeutics from a d rating to a c rating in a research report on Monday, October 28th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of Buy and an average price target of $69.54.
Shares of NASDAQ:CRSP traded down $2.64 during midday trading on Monday, reaching $69.01. The company’s stock had a trading volume of 1,323,338 shares, compared to its average volume of 1,463,663. The firm has a market capitalization of $4.00 billion, a PE ratio of -20.06 and a beta of 3.30. Crispr Therapeutics has a twelve month low of $22.22 and a twelve month high of $74.00. The stock has a fifty day moving average of $49.98 and a 200 day moving average of $46.23. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06.
Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.95) by $3.35. The firm had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. Sell-side analysts anticipate that Crispr Therapeutics will post 0.65 earnings per share for the current fiscal year.
In related news, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total value of $412,500.00. Following the sale, the director now directly owns 7,500 shares of the company’s stock, valued at approximately $412,500. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, President Rodger Novak sold 33,618 shares of the stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the sale, the president now directly owns 33,618 shares in the company, valued at $2,353,260. The disclosure for this sale can be found here. Over the last three months, insiders sold 56,118 shares of company stock worth $3,620,760. 21.40% of the stock is owned by corporate insiders.
Large investors have recently added to or reduced their stakes in the business. NEXT Financial Group Inc raised its holdings in Crispr Therapeutics by 915.0% in the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock valued at $25,000 after buying an additional 549 shares during the period. Coastal Investment Advisors Inc. acquired a new stake in shares of Crispr Therapeutics during the third quarter worth approximately $26,000. Benjamin Edwards Inc. grew its position in shares of Crispr Therapeutics by 96.4% during the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock worth $26,000 after buying an additional 268 shares in the last quarter. US Bancorp DE lifted its stake in Crispr Therapeutics by 553.7% during the second quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after purchasing an additional 526 shares during the last quarter. Finally, BSW Wealth Partners bought a new position in Crispr Therapeutics during the second quarter worth $39,000. Institutional investors own 49.81% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.